Patient description: The patient is a 41-year-old obese woman coming to the emergency room with abdominal pain and vomiting. The pain that started gradually yesterday is located in the epigastric and periumbilical regions, radiating to her back. She drinks alcohol frequently and does not smoke. She has no history of allergies and uses only multivitamins daily. Her family history is positive for hypertension (her mother). She lives with her husband and has 3 children. The abdomen is tender and soft. Her bowel sounds are normal. Her heart rate is 115/min and blood pressure 110/75 mmHg. The lab studies are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glucose level of 15. Her abdominal CT scan revealed acute edematous interstitial pancreatitis with enlarged common bile duct and intrahepatic duct confirming gall stone pancreatitis. Her pregnancy test is negative and she is not breastfeeding.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Pancreatic Disease Male or female, between the ages of 18-80 years old. 2. Clinical suspicion of pancreatic exocrine disease. 3. If female and not more than 1 year post-menopausal or surgically sterile, must use medically acceptable form of contraception or abstain from sexual activity during the study. Acceptable methods of birth control are: intrauterine device, implantable progesterone device, progesterone intramuscular injection, oral contraceptive (started at least one month prior to Screening Visit 1 and continuing for the duration of the trial), contraceptive patch, condoms with spermicide or abstinence. 4. EUS and ePFT planned for structural and functional evaluation of the exocrine pancreas. 5. Ability to undergo conscious sedation or monitored anesthesia. 6. Willing and able to sign written informed consent  Symptoms of acute pancreatitis within 30 days of the combined function test. 2. Severe cardiac disease (stable or unstable angina, congestive heart failure, uncontrolled arrhythmias, implantable defibrillator, severe valvular disease, etc). 3. Severe pulmonary disease (COPD, severe asthma, interstitial lung disease, etc). 4. Severe renal disease (history of acute or chronic renal failure and/or dialysis dependent and/or baseline creatinine >2.0 mg/dL). 5. Pregnant or nursing. 6. Ongoing illicit drug use or abuse. 7. Ongoing moderate or severe alcohol use defined by greater than 30 grams alcohol/day. 8. Acute pancreatitis as defined by the Atlanta Classification definition (see Appendix D) within the previous two months. 9. Prior pancreatic surgery. 10. Presence of a condition which may interfere with exocrine pancreatic functioning including celiac disease, type I diabetes mellitus, previous gastrectomy, cystic fibrosis or severe malnutrition (BMI <18). 11. Exhibiting signs or symptoms of an episode of acute pancreatitis. 12. Known allergy to secretin. 13. Recent (within 30 days) use of medication that can potentially cause pancreatitis, such as metronidazole, tetracycline, sulfonamides. 14. Use of any anticholinergic medication within 48 hours of enrollment. 15. Any medical condition which in the judgment of the Investigator renders participation in this study medically inadvisable. 16. Participation in an investigational clinical study for a drug or medical device within 30 days prior to Screening Visit 1. 17. Suspected or proven Sphincter of Oddi Dysfunction. 18. Previous pancreatic endoscopic or surgical sphincterotomy - -